Equities analysts expect Becton, Dickinson and Company (NYSE:BDX) to announce sales of $3.06 billion for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Becton, Dickinson and Company’s earnings. The highest sales estimate is $3.09 billion and the lowest is $3.04 billion. Becton, Dickinson and Company reported sales of $3.20 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.4%. The company is scheduled to issue its next earnings results before the market opens on Thursday, August 3rd.

According to Zacks, analysts expect that Becton, Dickinson and Company will report full year sales of $3.06 billion for the current fiscal year, with estimates ranging from $12.01 billion to $12.11 billion. For the next fiscal year, analysts anticipate that the company will report sales of $12.60 billion per share, with estimates ranging from $12.49 billion to $12.82 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Becton, Dickinson and Company.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.07. The firm had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.92 billion. Becton, Dickinson and Company had a return on equity of 25.37% and a net margin of 10.67%. The business’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.18 EPS.

Several research analysts have recently weighed in on BDX shares. Zacks Investment Research upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating and set a $206.00 price target for the company in a research note on Tuesday, April 11th. Raymond James Financial, Inc. raised Becton, Dickinson and Company from an “outperform” rating to a “strong-buy” rating and cut their price objective for the stock from $210.00 to $180.00 in a report on Friday, June 30th. BidaskClub raised Becton, Dickinson and Company from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $200.00 price objective on shares of Becton, Dickinson and Company in a report on Wednesday, March 29th. Finally, Evercore ISI raised Becton, Dickinson and Company from an “in-line” rating to an “outperform” rating and lifted their price objective for the stock from $186.00 to $200.00 in a report on Monday, April 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $190.18.

In other Becton, Dickinson and Company news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the sale, the vice president now directly owns 70,821 shares in the company, valued at $13,171,289.58. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.40% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of BDX. Chevy Chase Trust Holdings Inc. increased its stake in shares of Becton, Dickinson and Company by 3.1% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 265,398 shares of the medical instruments supplier’s stock worth $51,782,000 after buying an additional 8,024 shares during the period. Somerset Trust Co increased its stake in shares of Becton, Dickinson and Company by 2.8% in the second quarter. Somerset Trust Co now owns 10,654 shares of the medical instruments supplier’s stock worth $2,078,000 after buying an additional 288 shares during the period. First United Bank Trust increased its stake in shares of Becton, Dickinson and Company by 5.1% in the second quarter. First United Bank Trust now owns 7,382 shares of the medical instruments supplier’s stock worth $1,440,000 after buying an additional 355 shares during the period. National Pension Service increased its stake in shares of Becton, Dickinson and Company by 10.3% in the second quarter. National Pension Service now owns 171,227 shares of the medical instruments supplier’s stock worth $33,086,000 after buying an additional 15,996 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in shares of Becton, Dickinson and Company by 5.8% in the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock valued at $6,438,000 after buying an additional 1,819 shares during the last quarter. Institutional investors and hedge funds own 75.41% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) traded down 0.0672% on Thursday, reaching $198.0168. The company’s stock had a trading volume of 215,452 shares. The stock has a 50-day moving average of $190.01 and a 200 day moving average of $181.27. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $198.49. The company has a market cap of $42.24 billion, a price-to-earnings ratio of 32.8877 and a beta of 1.05.

The company also recently announced a quarterly dividend, which was paid on Friday, June 30th. Investors of record on Friday, June 9th were given a $0.73 dividend. The ex-dividend date of this dividend was Wednesday, June 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. Becton, Dickinson and Company’s dividend payout ratio is currently 48.26%.

TRADEMARK VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/08/3-06-billion-in-sales-expected-for-becton-dickinson-and-company-nysebdx-this-quarter-updated-updated-updated.html.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get a free copy of the Zacks research report on Becton, Dickinson and Company (BDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.